Acute lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) is a common cause of respiratory failure in critically ill patients, and afflicts ~200,000 Americans each year with ~75000 deaths and 3.6 million hospital days. The hallmark of ALI is vascular dysfunction characterized by endothelial cell (EC) inflammation and barrier disruption resulting in inflammatory infiltrates, interstitial edema, alveolar flooding, and ultimately respiratory failure. All current therapies for ALI/ARDS rely on supportive care to improve clinical outcome. No effective drugs have been developed. Thus, there is an urgent need to develop new treatment strategies for ALI/ARDS that are safe, effective, and based on deeper understanding of the mechanisms involved in ALI pathogenesis. Our long-term goal is to identify viable therapeutic targets and mechanisms to limit ALI. The objective of this application is to determine the role of ER chaperone BiP (immunoglobulin heavy chain binding protein) and mitochondrial chaperone mortalin in mediating EC barrier dysfunction and inflammation in ALI and assess the therapeutic benefit of targeting these molecules against ALI. The proposal is based on our novel findings that implicate an important role for BiP and mortalin in mediating inflammatory signaling and barrier disruption in EC and lung PMN infiltration and vascular leak in a mouse model of ALI. Our encouraging data show that pharmacological inhibitor of BiP or mortalin each protects against lung injury. Intriguingly, however, the combined inhibition of BiP and mortalin is effective at much lower dosage of each inhibitor (which alone shows no protective effect) in protecting against LPS-induced lung injury and mortality in mice. These exciting findings have led us to the hypothesis that BiP and mortalin are critical determinants of ALI by their ability to promote EC permeability and inflammation, and that combined inhibition of BiP and mortalin may prove a highly efficacious therapeutic intervention to control ALI. The proposal will address the following aims.
Aim 1 will determine (i) the mechanism of BiP regulation of EC permeability and inflammation and (ii) in vivo role of endothelial BiP in causing lung inflammation and injury.
Aim 2 will determine (i) the mechanism by which mortalin regulates EC permeability and inflammation and (ii) in vivo role of endothelial mortalin in causing lung inflammation and injury.
Aim 3 will evaluate the preventive and therapeutic potential of simultaneous targeting (combined inhibition) of BiP and mortalin against ALI and mortality in mice. These studies will utilize a combination of cellular, molecular, biochemical, pharmacological, imaging, in vivo gene transfer, and lung physiology. The creative integration of in vitro and in vivo studies will provide novel insights into BiP and mortalin regulation of EC inflammation and permeability during ALI and may lead to novel therapeutic interventions to control ALI/ARDS.

Public Health Relevance

/ RELVANCE TO PUBLIC HEALTH Acute lung Injury (ALI) is a common disease with an incidence of ~ 200,000 cases each year in the United States alone. Despite the use of state-of-the-art treatment, ALI is associated with an unacceptably high mortality rate and accounts for ~75000 deaths in the United States every year. The proposed studies are designed to gain novel insights into pathogenesis of ALI by studying the action of BiP and mortalin, representative chaperones of two important cell organelles, endoplasmic reticulum (ER) and mitochondria respectively, in endothelial cells (cells that form the inner lining of blood vessels) in the lung. We will use this new information to develop a new therapeutic strategy that relies on the combined inhibition of BiP and mortalin and evaluate its effectiveness in preventing and treating ALI in mice. This is an exciting new concept that may lead to an effective and safe treatment strategy to control ALI.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL130870-03
Application #
9520393
Study Section
Respiratory Integrative Biology and Translational Research Study Section (RIBT)
Program Officer
Aggarwal, Neil Raj
Project Start
2016-08-15
Project End
2020-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Rochester
Department
Pediatrics
Type
School of Medicine & Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Barnett, Rebecca C; Lin, Xin; Barravecchia, Michael et al. (2017) Featured Article: Electroporation-mediated gene delivery of surfactant protein B (SP-B) restores expression and improves survival in mouse model of SP-B deficiency. Exp Biol Med (Maywood) 242:1345-1354
Jain, Sumeet V; Kollisch-Singule, Michaela; Satalin, Joshua et al. (2017) The role of high airway pressure and dynamic strain on ventilator-induced lung injury in a heterogeneous acute lung injury model. Intensive Care Med Exp 5:25
Bijli, Kaiser M; Fazal, Fabeha; Slavin, Spencer A et al. (2016) Phospholipase C-? signaling mediates endothelial cell inflammation and barrier disruption in acute lung injury. Am J Physiol Lung Cell Mol Physiol 311:L517-24